SCHEMBL4777988

SCHEMBL4777988

COc1cccc(OCC(N)=O)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.72
SMN1; SMN2 Q16637 2/20 0.59
KDM4E B2RXH2 1/20 0.59
NPC1 O15118 1/20 0.59
TP53 P04637 1/20 0.59
RECQL P46063 1/20 0.59
RAB9A P51151 1/20 0.59
MAPK10 P53779 1/20 0.59
GAA P10253 4/20 0.56
PARP1 P09874 1/20 0.56
KMT2A Q03164 2/20 0.56
MAPT P10636 2/20 0.56
ALDH1A1 P00352 1/20 0.55
MEN1 O00255 1/20 0.55
MTNR1A P48039 3/20 0.54
MTNR1B P49286 3/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CYP1A2 P05177 2/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2C19 P33261 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11212235 0.86 TP53 (0.55) LMNASMN1; SMN2KDM4ETP53GAA
SCHEMBL1818582 0.85 LMNA (0.50) LMNASMN1; SMN2KDM4ENPC1TP53
SCHEMBL594554 0.84 LMNA (1.00) LMNAKDM4ENPC1GAAKMT2A
SCHEMBL8302834 0.84 LMNA (0.74) LMNASMN1; SMN2KDM4ENPC1TP53
SCHEMBL30785439 0.84 LMNA (1.00) LMNAKDM4ENPC1GAAKMT2A
SCHEMBL6170041 0.83 LMNA (0.54) LMNASMN1; SMN2KDM4ENPC1TP53
SCHEMBL14668844 0.83 MTNR1A (0.59) LMNASMN1; SMN2KDM4ENPC1TP53
SCHEMBL9731633 0.82 WDR5 (0.65) LMNASMN1; SMN2KDM4ENPC1TP53
SCHEMBL1308472 0.82 LMNA (0.72) LMNASMN1; SMN2KDM4ENPC1TP53
SCHEMBL7293057 0.82 LMNA (0.72) LMNASMN1; SMN2KDM4ENPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115160313-A 2-phenylimidazole [1,2-a ] pyridine compound, composition containing same and application of two compounds 中国药科大学 2022-10-11 CN disclosed
EP-2875001-B1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS SUNSHINE LAKE PHARMA CO LTD (CN) 2019-01-09 EP disclosed
US-9434695-B2 Nitrogenous heterocyclic derivatives and their application in drugs SUNSHINE LAKE PHARMA CO., LTD (CN) 2016-09-06 US disclosed
CN-103570630-B Nitrogen heterocyclic derivative and the application in medicine thereof SUNSHINE LAKE PHARMA CO.,LTD. (CN) 2016-04-20 CN disclosed
EP-2755949-B1 FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES BAYER IP GMBH (DE) 2015-10-21 EP disclosed
US-9090600-B2 Fungicidal 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadizol-5(4H)-one derivatives BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-07-28 US disclosed
EP-2875001-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS Sunshine Lake Pharma Co., Ltd. (CN) 2015-05-27 EP disclosed
US-20150087639-A1 Nitrogenous Heterocyclic Derivatives And Their Application In Drugs SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-03-26 US disclosed
US-20140349848-A1 FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-11-27 US disclosed
EP-2755949-A1 FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES Bayer Intellectual Property GmbH (DE) 2014-07-23 EP disclosed
CN-103570630-A Heterocyclic nitrogen derivative and application thereof in medicines GUANGDONG HEC PHARMACEUTICAL 2014-02-12 CN disclosed
WO-2014012360-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-01-23 WO disclosed
WO-2013037717-A1 FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-03-21 WO disclosed
WO-2008016811-A2 AMINOPIPERIDINES AND REALTED COMPOUNDS NEUROGEN CORPORATION (US) 2008-02-07 WO disclosed
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed
EP-0341694-B1 Method for production of 3-exomethylenecepham derivatives OTSUKA KAGAKU KK (JP) 1995-09-06 EP disclosed
US-4958018-A REACTING A 3-HALOMETHYL-3-CEPHEM WITH A LEAD REDUCING AGENT OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1990-09-18 US disclosed
EP-0341694-A2 Method for production of 3-exomethylenecepham derivatives OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1989-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349848-A1 FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES CYP4X1, CYP4B1, CYP4Z1 LMNA 3306/4885SMN1; SMN2 1570/4885KDM4E 294/4885
US-20150087639-A1 Nitrogenous Heterocyclic Derivatives And Their Application In Drugs TNNC1, TNNI3, IAPP LMNA 354/4885SMN1; SMN2 18/4885KDM4E 4181/4885
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 LMNA 2932/4885SMN1; SMN2 1509/4885KDM4E 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.